WO2019151514A1 - Inducteur de différenciation de monocytes contenant de l'albendazole - Google Patents

Inducteur de différenciation de monocytes contenant de l'albendazole Download PDF

Info

Publication number
WO2019151514A1
WO2019151514A1 PCT/JP2019/003802 JP2019003802W WO2019151514A1 WO 2019151514 A1 WO2019151514 A1 WO 2019151514A1 JP 2019003802 W JP2019003802 W JP 2019003802W WO 2019151514 A1 WO2019151514 A1 WO 2019151514A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
differentiation
leukemia
albendazole
monocyte
Prior art date
Application number
PCT/JP2019/003802
Other languages
English (en)
Japanese (ja)
Inventor
剣 森田
壯一 足立
正敏 萩原
Original Assignee
国立大学法人京都大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人京都大学 filed Critical 国立大学法人京都大学
Publication of WO2019151514A1 publication Critical patent/WO2019151514A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Definitions

  • This application relates to a monocyte differentiation inducer containing albendazole as an active ingredient.
  • hematopoietic stem cells there are diseases caused by inhibition of the differentiation process of hematopoietic stem cells, and examples include leukemia, aplastic anemia, and Costman syndrome.
  • Leukemia is a disease thought to occur when hematopoietic stem cells (or slightly differentiated cells) become tumors.
  • Chemotherapy is the basis of definitive treatment in leukemia.
  • chemotherapy requires a sufficient general state and organ function to withstand organ toxicity and complications.
  • elderly patients with leukemia who are unable to apply therapy and have no cure.
  • Differentiation induction therapy is known as a treatment for leukemia with few side effects.
  • differentiation-inducing therapy leukemia cells that continue to proliferate while remaining in the state of progenitor cells are killed by the normal life of normal leukocytes by differentiation and maturation, so leukemia cells such as many anticancer drugs and chemotherapy There are fewer side effects compared to treatments that directly destroy.
  • ATRA all-trans retinoic acid
  • arsenic as a differentiation-inducing agent for neutrophils.
  • no effective differentiation induction therapy has been established.
  • Acute promyelocytic leukemia is ATRA-resistant.
  • a new differentiation induction therapy effective for a wide range of leukemias is strongly desired in the medical field.
  • Aplastic anemia is a disease in which the differentiation process is inhibited by some abnormality in hematopoietic stem cells, and Costman syndrome (also known as severe congenital neutropenia) is found to inhibit the maturation of myeloid granulocyte cells.
  • Costman syndrome also known as severe congenital neutropenia
  • neutrophils decrease.
  • neutrophil differentiation inducers such as granulocyte colony stimulating factor (G-CSF) are currently administered. There are cases where it does not increase.
  • G-CSF granulocyte colony stimulating factor
  • An object of the present application is to provide a novel blood cell differentiation inducer.
  • albendazole a parasite-controlling agent
  • albendazole unexpectedly strongly induces differentiation of leukemia cells into monocyte-like cells
  • albendazole induces differentiation of normal progenitor cells into monocytes. That is, the present application provides a monocyte differentiation inducer containing albendazole.
  • the invention of the present application will be described in detail below.
  • [5] The agent for inducing differentiation of monocytes according to any one of [2] to [4], wherein the leukemia or a related disease thereof is chronic myelogenous leukemia, acute myeloid leukemia or myelodysplastic syndrome.
  • [7] A method for inducing differentiation into monocytes, comprising administering an effective amount of albendazole to a subject in need thereof. [8] The method according to [7], wherein the method is used in the treatment of a disease involving inhibition of the differentiation process of hematopoietic stem cells.
  • Albendazole for use in inducing monocyte differentiation.
  • Albendazole has a high differentiation-inducing activity toward monocytes and can be used as a monocyte differentiation-inducing agent. Furthermore, albendazole is already on the market as a therapeutic agent for hydatid disease (echinococcosis), and since data on safety to humans is accumulated, a safe monocyte differentiation inducer can be provided.
  • THP-1 cells of Test Example 3-1 were collected by treatment with 3 ⁇ M doxycycline for 48 hours, and cell surface expression of CD11b and CD14 was measured by flow cytometry.
  • Data are mean ⁇ SEM values. * P ⁇ 0.05, *** P ⁇ 0.001, two-sided student t test.
  • THP-1 cells treated with albendazole were measured by flow cytometry. Representative microscopic images of THP-1 cells of Test Example 4-3. Growth curves in the presence of 1 nMPMA of THP-1 cells transduced with shRNA targeting KLF4 (sh_KLF4 # 1 and # 2), DPYSL2A (sh_DPYSL2A # 1 and # 2) or control luciferase (sh_Luc.).
  • This application provides a monocyte differentiation inducer containing albendazole as an active ingredient.
  • the monocyte differentiation inducer of the present application can be used, for example, to treat a disease accompanied by inhibition of the differentiation process of hematopoietic stem cells.
  • the monocyte differentiation inducer of the present application can be used for patients with reduced neutrophils or monocytes regardless of the presence or absence of a disease accompanied by inhibition of the differentiation process of hematopoietic stem cells. It can be used to prevent or ameliorate symptoms that can be caused by a decrease in spheres or monocytes (eg, bacterial infections).
  • Albendazole [Chemical name: (methyl 5- (propylthio) -2-benzimidazolecarbamate)] Is known as a benzimidazole-type anthelmintic agent and has already been marketed as a therapeutic agent for encaustic diseases (eg, echinococcosis) (for example, Escazole (registered trademark) tablets in Japan). The action is thought to be due to the inhibition of tubulin binding to the colchicine binding site and the formation of microtubules.
  • encaustic diseases eg, echinococcosis
  • Escazole registered trademark
  • JP-T-2004-525140, JP-T-2008-522984, and JP-T-2016-535014 disclose solid cancers such as liver cancer, colon cancer, pancreatic cancer, ovarian cancer and the like using albendazole known as an anthelmintic agent. However, it does not describe a specific effect on leukemia. Moreover, these literatures do not describe induction of blood cell differentiation by albendazole.
  • albendazole may be synthesized by a known method, or may be obtained as a commercial product (for example, Tokyo Chemical Industry Co., Ltd.). Albendazole may also be in the form of a pharmaceutically acceptable salt or hydrate.
  • monocyte differentiation induction means a hematopoietic stem cell (strictly not a hematopoietic stem cell but an immature cell group that has the ability to differentiate into both myeloid and lymphoid cells (eg, c-kit surface antigen positive cells) And / or induce differentiation of myeloid hematopoietic progenitor cells into monocytes.
  • Monocytes differentiated by the monocyte differentiation inducer of the present application are at least one of the morphological features commonly used to identify monocytes (eg, notched or partially depressed) With nuclei; with basophil cytoplasmic granules (azurole granules); with vacuoles in the cytoplasm) and / or with features based on surface antigen classification (eg CD11b positive and CD14 positive) and self-proliferating ability And cells that do not have the ability to immortalize.
  • the gene information of the monocytes induced to differentiate is not particularly limited, and for example, gene information derived from a disease can be retained.
  • myeloid hematopoietic progenitor cell means a progenitor cell found in the process of differentiation from a hematopoietic stem cell into a myeloid blood cell, such as a myeloid hematopoietic stem cell and a mature differentiated cell from a myeloid hematopoietic stem cell. It means a progenitor cell in the process of differentiation into (for example, mast cell, basophil, eosinophil, neutrophil, monocyte, megakaryocyte, or erythrocyte).
  • myeloid hematopoietic progenitor cells include: myeloid hematopoietic stem cells, granule / monocytic stem cells, erythroblast / megakaryocytic stem cells, myeloblasts, promyelocytes, myelospheres, postmyelocytes, rods Examples thereof include nuclear spheres, segmented nucleus nuclei, monoblasts, pre-monocytes, pre-erythroblasts, erythroblasts, and pre-megakaryocytes.
  • Hematopoietic stem cells which are not strictly hematopoietic stem cells but include immature cells that have the ability to differentiate into both myeloid and lymphoid
  • myeloid progenitor cells are normal even if they are normal cells. (For example, canceration).
  • the monocyte differentiation inducer of the present application includes hematopoietic stem cells (including not strictly hematopoietic stem cells but immature cells and cells capable of differentiating into both myeloid and lymphoid systems) and / or myeloid progenitors.
  • hematopoietic stem cells including not strictly hematopoietic stem cells but immature cells and cells capable of differentiating into both myeloid and lymphoid systems
  • myeloid progenitors can treat diseases involving inhibition of the differentiation process of hematopoietic stem cells (eg, aplastic anemia, Costman syndrome, or leukemia or related diseases (eg myelodysplastic syndrome)) .
  • Aplastic anemia is susceptible to severe bacterial infections such as pneumonia and sepsis because the differentiation process is inhibited by some abnormality in hematopoietic stem cells, and blood cells in blood, particularly neutrophils, decrease.
  • Costman syndrome also known as severe congenital neutropenia
  • severe congenital neutropenia is a group of diseases in which severe chronic neutropenia is observed due to genetic mutation, and bacterial infections occur repeatedly.
  • Diagnosis by the bone marrow image shows inhibition of maturation of bone marrow granulocyte cells.
  • the monocyte differentiation inducer of the present application is a symptom (for example, bacterial infection) that is accompanied by a decrease in blood cells (particularly neutrophils) in addition to their fundamental treatment, for example.
  • a symptom for example, bacterial infection
  • blood cells particularly neutrophils
  • the functions of macrophages matured from monocytes to bacterial infection are similar to those of neutrophils.
  • symptoms such as bacterial infections can be treated. Can be done.
  • Leukemia is a disease thought to occur when hematopoietic stem cells (or slightly differentiated cells) become tumors.
  • Tumorized cells (leukemia cells) grow abnormally and occupy the bone marrow, and normal hematopoietic function is significantly inhibited.
  • red blood cells, normal white blood cells, and platelets decrease, and as the disease progresses, enlargement of the spleen, liver, and lymph nodes due to infiltration of leukemia cells begins to occur.
  • leukemia cells which are progenitor cells that have been differentiated to a certain stage, have proliferated (acute leukemia) and have the ability to differentiate and mature (chronic leukemia). It is divided roughly into. They are also classified into myeloid leukemia and lymphocytic leukemia depending on the cancerous cell lineage.
  • FAB classification based on morphological classification is known.
  • acute myeloid leukemia and acute lymphoblastic leukemia are roughly classified by peroxidase staining, and acute myeloid leukemia is further classified into the following M0 to M7.
  • the “leukemia” that can be treated with the monocyte differentiation inducer of the present application is not particularly limited as long as it is determined as leukemia based on general criteria used by doctors or researchers. Since the monocyte differentiation inducer of the present application has the ability to induce differentiation from myeloid hematopoietic progenitor cells to monocytes, it is preferably used for the treatment of acute and / or chronic myeloid leukemia, particularly preferably acute myeloid Used to treat leukemia.
  • the monocyte differentiation inducer of the present application can induce differentiation of abnormally proliferating leukemia cells into monocytes in the treatment of leukemia.
  • leukemia cells can be induced to differentiate into monocytes lacking the ability of self-proliferation and immortalization, and can be killed gently with the original short life span of normal monocytes. That is, the monocyte differentiation inducer of the present application can be used as differentiation induction therapy.
  • the monocyte differentiation inducer of the present application can gently kill leukemia cells, side effects (eg, anorexia, nausea, vomiting, diarrhea, etc.) that may occur with conventional chemotherapeutic agents with cell killing action Symptoms, fever, general malaise, sepsis, hair loss, acute respiratory distress syndrome, interstitial pneumonia, liver dysfunction, jaundice, arrhythmia, heart failure, gastrointestinal dysfunction, central nervous system disorder, liver abscess, acute pancreatitis, lung edema, Painful erythema, CRP elevation, ALT (GPT) elevation, AST (GOT) elevation, etc.) can be suppressed.
  • side effects eg, anorexia, nausea, vomiting, diarrhea, etc.
  • MDS myelodysplastic syndrome
  • the monocyte differentiation inducer of the present application can induce the differentiation of immature abnormal cells and gently kill them in the treatment of myelodysplastic syndromes as well as leukemia.
  • the monocyte differentiation inducer of the present application can improve the level of monocytes in the treatment of leukemia or related diseases, and prevent various symptoms (for example, bacterial infections etc.) caused by neutrophil / monocyte depletion. It can also be used for improvement.
  • treatment refers to treating disease, preventing disease, alleviating disease symptoms, delaying disease progression, suppressing disease symptoms, ameliorating disease symptoms, And inducing amelioration of disease symptoms.
  • the “effective amount” is the amount of the active agent necessary to give the patient the benefit of inducing differentiation of monocytes.
  • albendazole can be administered in combination with other drugs simultaneously, separately or sequentially.
  • albendazole and the other drug may be included in the same formulation or in separate formulations. When included in separate formulations, they may be administered simultaneously via the same or different routes of administration.
  • albendazole and the other agent may be administered separately according to different dosing schedules and may be administered by different routes of administration.
  • any agent may be administered first.
  • the time between administration of one therapeutic agent and the other is preferably less than 8 hours. More preferably, it is less than 4 hours, and even more preferably, it is less than 1 hour.
  • drugs for example, carmustine, chlorambucil, lomustine, mechloretamine, azacitidine, acyclovir, L-asparaginase, Arsenite, alemtuzumab, idarubicin, ifosfamide, ibritumomab tiuxetan, imatinib, irinotecan, interferon alpha, etoposide, enocitabine, epirubicin, erythropoietin, ofatatumumab, all-trans retinoic acid, carbogetum zobin, Mycin, thalidomide, cyclosporine, cyclophosphamide, cisplatin, cytarabine, zidobucin, sobuzoxane, daunorubicin, daca
  • drugs for example, carmustine, chlorambucil, lomustine, mechloretamine, azacitidine
  • the albendazole-containing monocyte differentiation inducer in the present application is mixed with one or more pharmaceutically acceptable carriers, for example, tablets, capsules, granules, powders, troches, syrups, emulsions, suspensions, etc. Or a parenteral preparation such as an external preparation, a suppository, an injection, an eye drop, a nasal preparation, a pulmonary preparation and the like.
  • pharmaceutically acceptable carriers for example, tablets, capsules, granules, powders, troches, syrups, emulsions, suspensions, etc.
  • a parenteral preparation such as an external preparation, a suppository, an injection, an eye drop, a nasal preparation, a pulmonary preparation and the like.
  • Examples of preferable dosage forms of the monocyte differentiation inducer according to the present application include tablets and injections.
  • the carrier / additive contained in the oral preparation of the present application is not particularly limited as long as it is a pharmaceutically acceptable one that is usually used.
  • Excipients such as lactose, sucrose, D-mannitol, D-sorbitol, corn starch, dextrin, microcrystalline cellulose, crystalline cellulose, carmellose, carmellose calcium, sodium carboxymethyl starch, low substituted hydroxypropylcellulose, and arabic Rubber);
  • Disintegrants eg, carmellose, carmellose calcium, carmellose sodium, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, low substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, and crystalline cellulose
  • Binders eg, hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, crystalline cellulose, sucrose, dextrin, starch, gelatin, carmellose sodium, and gum arabic
  • Fluidizing agents eg, light anhydrous silicic acid
  • the carrier / additive contained in the liquid preparation (including injection) of the present application is not particularly limited as long as it is a pharmaceutically acceptable one that is usually used.
  • Solvent eg, water, ethanol, propylene glycol, macrogol, glycerin, etc.
  • Solubilizers eg, propylene glycol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate, trometamol (tris [hydroxymethyl] aminomethane), meglumine, etc.
  • Isotonic agents eg, glucose, glycerin, D-mannitol, D-sorbitol, sodium chloride, sucrose, potassium chloride, etc.
  • Buffers eg trisodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, boric acid, citric acid, sodium citrate, tartaric acid, acetic acid, sodium acetate, epsilon-aminocaproic acid
  • the amount of albendazole contained in the monocyte differentiation inducer according to the present application is not particularly limited and is selected in a wide range.
  • it is about 0.05% to about 90% by weight based on the composition.
  • it is preferably about 0.01 wt% to about 50 wt%, more preferably about 0.05 wt% to about 20 wt%, more preferably about 0.2 wt% to about 10 wt%.
  • a diluting solution eg, physiological saline
  • administered eg, intravenous administration
  • the dose of albendazole of the present application is appropriately selected depending on the administration method, the subject, the age of the subject, the degree of the disease, symptoms, dosage form, administration route, etc., for example, orally 0.1 mg per day It can be administered at a dose of ⁇ 100 g, preferably 1 mg to 50 g, more preferably 10 mg to 20 g, more preferably 100 mg to 10 g.
  • Examples of the lower limit of the daily dose of albendazole include 0.1 mg, 1 mg, 10 mg, 100 mg, and 400 mg, and examples of the upper limit include 700 mg, 1 g, 3 g, 5 g, 10 g, 20 g, 50 g and 100 g can be mentioned, and a preferable range of the daily dose of albendazole can be indicated by a combination of the upper limit value and the lower limit value.
  • the amount of albendazole per day may be administered in one to several divided doses.
  • the subject of administration of the monocyte differentiation inducer of the present application is not particularly limited, but is preferably a mammal (human and non-human mammals (eg, cows, horses, pigs, dogs, cats, mice, rats, rabbits, monkeys)). More preferably, it is a human.
  • a mammal human and non-human mammals (eg, cows, horses, pigs, dogs, cats, mice, rats, rabbits, monkeys)). More preferably, it is a human.
  • Kruppel-like transcription factor 4 is one of the KLF family transcription factors and is known to be suppressed in hematopoietic tumors (Non-patent Document 1).
  • Test Examples 1 to 3 below the present inventors have clarified that the signal pathway by KLF4 and its downstream factor DPYSL2A contributes to the differentiation from hematopoietic progenitor cells to monocytes ( Presented at American Society of Hematology in 2016: Non-Patent Document 2).
  • the inventors of the present application show that albendazole (ABZ) increases the expression of KLF4 and is highly active in inducing differentiation into monocytes through stimulation of DPYSL2A. It was revealed for the first time that the present invention was achieved.
  • the present invention will be described with reference to test examples, but the present invention is not limited to these test examples.
  • Acute myeloid leukemia (AML) -derived THP-1 and KG-1a cells were purchased from RIKEN biological resource center (BRC) (Japan).
  • BRC RIKEN biological resource center
  • SKNO-1 cells and fetal kidney-derived HEK293T cells were purchased from Japanese Collection of Research Bioresources (JCRB) (Japan).
  • AML-derived OCI-AML3 and MOLM-13 cells were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) (Germany).
  • DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
  • AML-derived MV4-11 and KG-1a cells were purchased from American Type Culture Collection (ATCC) (USA).
  • NB4 and UF-1 cells derived from acute promyelocytic leukemia (APL) were provided by Dr. Y.
  • HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (supplemented with 10% heat-inactivated fetal calf serum (FBS) and 1% penicillin-streptomycin (PS)) in a humidified environment of 5% CO 2 and 95% air, 37 Maintained in an incubator at 0 ° C. Other cells were cultured at 37 ° C. in 5% CO 2 and 95% air in Roswell Park Memorial Institute (RPMI) 1640 medium (containing 10% FBS and 1% PS).
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS heat-inactivated fetal calf serum
  • PS penicillin-streptomycin
  • MOLM-13 is a leukemia that developed from myelodysplastic syndrome (MDS).
  • MDS myelodysplastic syndrome
  • NB4 and UF-1 are all-trans retinoic acid (ATRA) resistant.
  • ⁇ IC 50 evaluation> For cell viability analysis, cells were seeded at a concentration of 1 ⁇ 10 5 cells / mL. A predetermined concentration of drug was added to the culture medium, and the cells were cultured for 48 hours. Followinged by WST assay Cell viability, Cell Count Reagent (nacalai tesque, Inc.) and Infinite was evaluated using as described in (TM) 200 PRO multimode reader the (TECAN) manufacturer. Depict percent inhibition curve, an IC 50 value of the drug median-effect method (Chou TC, Talalay P. Quantitative analysis of dose-effect relationships:.. The combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984; 22 : 27-55).
  • the primers used for qRT-PCR are shown in the table below.
  • CSIV-TRE-Ubc-KT Human KLF4, DPYSL2A and DPYSL2B cDNAs were amplified by PCR and then inserted into pENTR1A dual selection vector (Thermo Fisher Scientific), CSIV-TRE-Ubc-KT, and pLenti CMV Puro DEST (addgene) expression vectors.
  • CSIV-TRE-Ubc-KT was provided by Dr. H. Miyoshi (RIKEN, BRC, Japan). All PCR products were confirmed by DNA sequencing.
  • Lentivirus production is performed as described in Morita K, Suzuki K, Maeda S, et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. J Clin Invest. 2017; 127 (7): 2815-2828. It was. Briefly, HEK293T cells were transiently co-transfected with polyethyleneimine (PEI, Sigma-Aldrich) with lentiviral vectors (eg psPAX2 and pMD2.G).
  • PEI polyethyleneimine
  • lentiviral vectors eg psPAX2 and pMD2.G
  • the membrane was treated with the following primary antibodies: anti-KLF4 (# 4038, Cell Signaling Technology), anti-GAPDH (FL-335, Santa Cruz Biotechnology, Inc.), anti-DPYSL2 (HPA002381, Sigma-Aldrich), anti-DPYSL antibody (HPA002381, Sigma) -Aldrich) and HRP-conjugated anti-rabbit IgG and anti-mouse IgG (Cell Signaling Technology) were used as secondary antibodies. Blots were visualized using Chemi-Lumi One Super (nacalai tesque, Inc.) and ChemiDoc TM XRS + Imager (Bio-Rad Laboratories, Inc.) according to the manufacturer's recommendations. Protein levels were quantified using Image Lab Software (Bio-Rad Laboratories, Inc.).
  • ⁇ Statistics> The statistical significance of the difference between the control group and the test group was evaluated by a two-sided unpaired student t test, and was considered significant when the p value was less than 0.05. Equal variance in the two populations was calculated by F test. Results were expressed as mean ⁇ SEM values obtained from three independent tests. In the transplantation experiment, the animals were randomly divided into test groups, and the treatment was performed in a blinded manner. The survival rate of each group was compared using a log-rank test.
  • NOD / Shi-scid, IL-2R ⁇ KO (NOG) mice were purchased from Central Institute for Experimental Animals (Japan). Litters were used as controls for all studies.
  • ⁇ Xenograft mouse model A xenograft mouse model of a human cancer cell line was created using NOG mice.
  • THP-1 cells (2 ⁇ 10 6 cells / mouse) were administered intravenously.
  • Peripheral blood (PB) was collected weekly and chimerization was checked with anti-human CD45 antibody (BD Biosciences) by flow cytometer.
  • PB Peripheral blood
  • BD Biosciences anti-human CD45 antibody
  • mice received albendazole (50 mg / kg body weight, 2 times / week, oral (po)), or an equivalent amount of dimethyl sulfoxide (DMSO).
  • albendazole 50 mg / kg body weight, 2 times / week, oral (po)
  • DMSO dimethyl sulfoxide
  • THP-1 cells transduced with KLF4 or control encoding lentivirus were treated with 3 ⁇ M doxycycline for 48 hours, then harvested and cytospun onto glass slides. Each slide was subjected to Diff-Quik staining (modified Giemsa staining).
  • Diff-Quik staining modified Giemsa staining.
  • FIG. 1 A representative microscopic image of THP-1 cells is shown in FIG. As shown in FIG. 1, when KLF4 was overexpressed in the AML cell line, abnormal cells were induced to differentiate into monocyte-like cells.
  • DPYSL2A is a direct downstream factor of KLF4.
  • THP-1 and MOLM-13 cells transformed with lentivirus encoding KLF4 or control (Ctrl) were treated with 3 ⁇ M doxycycline for 48 hours, lysed for protein extraction, and immunoblotting of KLF4, DPYSL2A, and GAPDH Went. The results are shown in FIG.
  • KLF4 up-regulated DPYSL2A gene expression.
  • DPYSL2A is an important mediator of KLF4-induced differentiation.
  • Test Example 3-1 THP-1 cells transduced with a lentivirus encoding shRNA targeting KLF4 and DPYSL2A (sh_DPYSL2A # 1 and # 2) or control luciferase (sh_Luc.) Were treated with 3 ⁇ M doxycycline for 48 hours And then lysed for protein extraction and immunoblotted for KLF4, DPYSL2A and GAPDH. The results are shown in Fig. 3-1.
  • Test Example 3-2 THP-1 cells of Test Example 3-1 were collected by treatment with 3 ⁇ M doxycycline for 48 hours, and cell surface expression of CD11b and CD14 was measured by flow cytometry. The results are shown in Fig. 3-2.
  • Test Example 3-4 A representative microscopic image of the THP-1 cell of Test Example 3-1 is shown in FIG. 3-4. Cells were collected by treatment with 3 ⁇ M doxycycline for 48 hours and cytospun onto glass slides. Each slide was subjected to Diff-Quik staining (modified Giemsa staining).
  • THP-1 cells expressing KLF4 and DPYSL2A differentiated into monocyte-like cells, and after 5 days of culture, the cells were significantly different from those in which DPYSL2A was knocked down. The number has decreased.
  • Test Example 4-2 Cell surface expression of CD11b and CD14 in THP-1 cells treated with albendazole was measured by flow cytometry. Cells were treated with albendazole (1 ⁇ M) for 24 hours and harvested for flow cytometric analysis. The results are shown in Fig. 4-2.
  • Test Example 4-3 Representative microscopic image of THP-1 cells of Test Example 4-2. Diff-Quik staining (modified Giemsa staining) was performed on each slide. (Enlargement 20 ⁇ , scale bar: 50 ⁇ m). The results are shown in Fig. 4-3.
  • Test Example 4-4 Presence of 1 nMPMA in THP-1 cells transduced with shRNA targeting KLF4 (sh_KLF4 # 1 and # 2), DPYSL2A (sh_DPYSL2A # 1 and # 2) or control luciferase (sh_Luc.) The growth curve below. shRNA expression was induced with 3 ⁇ M doxycycline. The results are shown in Fig. 4-4.
  • albendazole increased the expression of KLF4 and DPYSL2A and differentiated THP-1 cells into monocyte-like cells.
  • FIG. 4-4 since the antitumor effect of albendazole was suppressed in cells knocked down with KLF4 or DPYSL2A, the expression of KLF4 by albendazole shows that such an antitumor effect appears. It was done.
  • the table below shows the IC 50 of ATRA and / or albendazole for each cell.
  • Albendazole showed a very low IC 50 for each leukemia cell.
  • IC 50 evaluation-II AML cell lines were treated with various concentrations of albendazole for 48 hours and IC 50 calculated. The results are shown in the table below. Albendazole showed a very low IC 50 for a wide variety of AML cells.
  • the albendazole and DMSO groups were treated with albendazole (50 mg / kg body weight, 2 times / week, po) or an equivalent amount of DMSO (control).
  • overall survival of the albendazole group was significantly prolonged compared to the DMSO group.
  • Test Example 7-2 Mice treated as in Test Example 7-1 were appropriately anesthetized and sacrificed. Bone marrow tissue was collected and hematoxylin and eosin (H & E) staining and immunohistochemical staining with anti-human CD45 antibody were performed on each slide. A representative image of the spleen and liver of an AML (THP-1 cell) xenograft mouse (30 days after transplantation) is shown in FIG. 6-3. As shown in FIG. 6-2, the proliferation of THP-1 cells was suppressed. As shown in FIG. 6-3, albendazole suppressed the enlargement of the liver and spleen.
  • Test Example 8 From the bone marrow cells of wild-type C57BL / 6 mice, c-Kit surface antigen was stained and positive cells (this cell is considered to be an immature cell that has hardly differentiated, and to both the myeloid and lymphatic systems. Were collected using a flow cytometer. 5000 collected c-kit surface antigen positive cells were seeded on a methylcellulose semi-solid medium, and albendazole was administered thereto at 0 nM, 100 nM, and 500 nM, and cultured at 37 ° C. for 1 week. One week later, colony formation was observed with a microscope and counted. The results are shown in FIG. As apparent from FIG. 7, the number of monocytic colonies increased from that of granulocyte colonies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un inducteur de différenciation de monocytes qui contient de l'albendazole utilisé comme principe actif.
PCT/JP2019/003802 2018-02-05 2019-02-04 Inducteur de différenciation de monocytes contenant de l'albendazole WO2019151514A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-018622 2018-02-05
JP2018018622A JP2021059495A (ja) 2018-02-05 2018-02-05 アルベンダゾール含有単球分化誘導剤

Publications (1)

Publication Number Publication Date
WO2019151514A1 true WO2019151514A1 (fr) 2019-08-08

Family

ID=67479688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/003802 WO2019151514A1 (fr) 2018-02-05 2019-02-04 Inducteur de différenciation de monocytes contenant de l'albendazole

Country Status (2)

Country Link
JP (1) JP2021059495A (fr)
WO (1) WO2019151514A1 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATCHETT, K. B. ET AL.: "High-throughput screen identification of albendazole as a novel repurposed drug in acute myeloid leukaemia", BLOOD, vol. 130, no. 1, 7 December 2017 (2017-12-07), pages 5062, ISSN: 1528-0020, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/130/Suppl_1/5062> [retrieved on 20190222] *
NAKAJIMA, 0. ET AL.: "Increase in the chemically-induced differentiation of human leukemia cell lines by tubulin disruptors", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 17, no. 5, 15 May 1994 (1994-05-15), pages 742 - 744, XP001149147, ISSN: 0918-6158 *
ZHAO, Y. ET AL.: "Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril", ORGANIC & BIOMOLECULAR, vol. 6, no. 24, 21 December 2008 (2008-12-21), pages 4509 - 4515, XP055628491, ISSN: 1477-0520 *

Also Published As

Publication number Publication date
JP2021059495A (ja) 2021-04-15

Similar Documents

Publication Publication Date Title
JP7432624B2 (ja) Ｎａｄ＋及び／又はｎａｄ＋阻害剤及び／又はｎａｄ＋アゴニストの使用及びその配合剤
Meshkibaf et al. Protective role of G-CSF in dextran sulfate sodium-induced acute colitis through generating gut-homing macrophages
US20180200301A1 (en) Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
JP7235259B2 (ja) Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
US11981924B2 (en) Composition for culturing NK cells and method for culturing NK cells using same
JPWO2015178426A1 (ja) がん幹細胞の増殖抑制剤
Guo et al. Genetically modified" obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma
US20150272992A1 (en) Treatment of Tumors with Activated Mesenchymal Stem Cells
US20210128639A1 (en) Cell preparation for treating brain tumor
Fowler et al. Targeting the canonical nuclear factor-κB pathway with a high-potency IKK2 inhibitor improves outcomes in a mouse model of idiopathic pneumonia syndrome
Hossain et al. N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification
KR20220026959A (ko) 엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물
WO2019151514A1 (fr) Inducteur de différenciation de monocytes contenant de l&#39;albendazole
CN117045801A (zh) m6A RNA甲基化酶抑制剂与免疫检查点抑制剂联合治疗肿瘤
Gu et al. Enhancing fatty acid catabolism of macrophages within aberrant breast cancer tumor microenvironment can re-establish antitumor function
WO2011088402A2 (fr) Utilisation de neutrophiles entraînés pour traiter une maladie métastatique et micrométastatique chez des patients à risque
WO2021073610A1 (fr) Procédés et compositions pour améliorer des fonctions hématopoïétiques de la moelle osseuse
US20230059785A1 (en) Methods for enhancing t cells using venetoclax
Wei et al. Genkwanin attenuates lung cancer development by repressing proliferation and invasion via phosphatidylinositol 3-kinase/protein kinase B pathway
JP2019131505A (ja) 抗がん剤
US20230365973A1 (en) Fats as a target for treating tumors and uses thereof
CN109913413B (zh) 一种加载pd-1抗体的t细胞体外培养方法、其细胞制剂及其应用
Ngwa Targeting Vascular Endothelial Glutaminase in Triple Negative Breast Cancer
TWI690327B (zh) 西瑞香素於預防組織或器官移植排斥或是移植物抗宿主疾病之用途
Wang The Role of LIF in Tissue Homeostasis, Disease, and Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19747601

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19747601

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP